Discontinued — last reported Q3 '25
Reportable Segment — Income taxes (Note 14)
Eli Lilly Reportable Segment — Income taxes (Note 14) increased by 47.9% to $1.65B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 166.9%, from $618.10M to $1.65B. Over 2 years (FY 2022 to FY 2024), Reportable Segment — Income taxes (Note 14) shows an upward trend with a 92.9% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase in this metric typically reflects higher segment profitability, though it may also indicate changes in the geographic mix of earnings or shifts in tax legislation affecting the segment's operations. A decrease may signal lower taxable income or the realization of tax benefits and credits.
Detailed definition
This metric represents the total income tax expense allocated to a specific reportable operating segment. It reflects th...
Peer comparison
Most large pharmaceutical companies report segment-level tax expenses to provide transparency into regional tax efficiency and the impact of global tax strategies on segment margins.
lly_segment_reportable_segment_income_taxes_note_14Historical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $140.40M | $140.40M | $140.40M | $140.40M | $328.55M | $328.55M | $328.55M | $328.55M | $293.20M | $550.20M | $618.10M | $628.90M | $696.80M | $1.12B | $1.65B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +134.0% | +0.0% | +0.0% | +0.0% | -10.8% | +87.7% | +12.3% | +1.7% | +10.8% | +60.1% | +47.9% |
| YoY Change | — | — | — | — | +134.0% | +134.0% | +134.0% | +134.0% | -10.8% | +67.5% | +88.1% | +91.4% | +137.7% | +102.8% | +166.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's reportable segment — income taxes (note 14)?
- Eli Lilly (LLY) reported reportable segment — income taxes (note 14) of $1.65B in Q3 2025.
- How has Eli Lilly's reportable segment — income taxes (note 14) changed year-over-year?
- Eli Lilly's reportable segment — income taxes (note 14) increased by 166.9% year-over-year, from $618.10M to $1.65B.
- What is the long-term trend for Eli Lilly's reportable segment — income taxes (note 14)?
- Over 2 years (2022 to 2024), Eli Lilly's reportable segment — income taxes (note 14) has grown at a 92.9% compound annual growth rate (CAGR), from $561.60M to $2.09B.
- What does reportable segment — income taxes (note 14) mean?
- The amount of income tax expense attributed to the operations of a specific business segment.